Bowel perforation after erlotinib treatment in a patient with non-small cell lung cancer |
| |
Authors: | Cheon Yun-Hong Kim Moon Jin Kang Min Gyu Kim Hee Jin Lee Sang Su Kim Cha Young Jeon Dae-Hong Kim Yu Eun Lee Gyeong-Won |
| |
Affiliation: | Division of Oncology-Hematology, Department of Internal Medicine, School of Medicine, Gyeongsang National University, 79 Gangnam-ro, Jinju 660-702, Korea. brightree@lycos.co.kr |
| |
Abstract: | Erlotinib is accepted as a standard second-line chemotherapeutic agent in patients with non-small cell lung cancer who are refractory or resistant to first-line platinum- based chemotherapy. There has been no previous report of bowel perforation with or without gastrointestinal metastases related to erlotinib in patients with non-small cell lung cancer. The exact mechanism of bowel perforation in patients who received erlotinib remains unclear. In this report, we report the first case of enterocutaneous fistula in a female patient with metastatic non-small cell lung cancer 9 months, following medication with erlotinib as second-line chemotherapy. |
| |
Keywords: | Lung neoplasm intestinal fistula erlotinib |
本文献已被 PubMed 等数据库收录! |
|